{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 23,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide presents preclinical data supporting the efficacy of NXP900 in combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/19",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.73,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Relative BLI signal Normalised to Day 14",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76b2e3c6-a1f2-4bb5-9940-7da4f64ab890",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.26,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Osimertinib re-sensitisation in PC-9",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e960914-e55c-4dfd-8cb3-fc5b414bd9b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Osimertinib resistance in PC-9",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb9c22dc-fab2-4b5c-93de-42ecdea7122d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.3,
        "y": 0.96
      },
      "kind": "disclaimer",
      "text": "NSCLC = non-small cell lung cancer, mCRPC = metastatic castration resistant prostate cancer, eCF506 = NXP900",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47c9aaa2-1691-44eb-bc0d-73a0bb3aecd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.53,
        "y": 0.45
      },
      "kind": "image",
      "text": "In vivo mouse model imaging",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8875ca2d-289b-4636-b8b1-724a1ef9e8b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "YES1 (in NSCLC) and SRC (in mCRPC) are implicated in development of resistance to osimertinib (Tagrisso) and enzalutamide (Xtandi)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea633654-2eff-434d-9823-7e6d6eb0e1cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "Published in JEM by UoE and MSKCC, February 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76b9e551-9c48-47a2-a806-14db33cd3c7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "Published in Nature Communications by the AstraZeneca R&D Group, April 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94aceaba-2a03-4ae8-ba31-84669884f2e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Potential Combination Strategies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c10cceb-75ab-4c42-8df9-5c335b1721dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7e447b5d-aa17-4faf-88b6-6d6dc58b352b",
      "evidence": "The deck presents data on the significant single agent activity of NXP900 in squamous cell cancers.",
      "position": 1,
      "objective": "Present NXP900 as a potential game-changer in squamous cell cancers",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}